IR Summary

Progen Pharmaceuticals Limited is a dual listed Australian company. Our primary listing is on the Australian Securities Exchange (ASX) and our secondary listing is on the US NASDAQ Capital Market (NASDAQ).
Progen has operations in Australia and the US.

Key Statistics

Ownership: Public
Exchanges: ASX, NASDAQ
Ticker Symbols: ASX: PGL; NASDAQ: PGLA
Exchange Listing Dates: ASX: 1995; NASDAQ: 1997

Our Vision

Progen’s vision is two-fold: to improve cancer patients’ lives by providing them with improved oncology solutions; and to create long-term shareholder value through the discovery and development of novel cancer therapeutics.